Get the Stockscreener App
2.35
2.08%
-0.05
After Hours:
2.33
-0.02
-0.85%
Anixa Biosciences Inc stock is traded at $2.35, with a volume of 111.10K.
It is down -2.08% in the last 24 hours and down -21.67% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$2.40
Open:
$2.4
24h Volume:
111.10K
Relative Volume:
1.02
Market Cap:
$78.79M
Revenue:
$210.00K
Net Income/Loss:
$-10.40M
P/E Ratio:
-7.4627
EPS:
-0.3149
Net Cash Flow:
$-6.88M
1W Performance:
-6.75%
1M Performance:
-21.67%
6M Performance:
-54.19%
1Y Performance:
-32.66%
1-Day Range:
$2.35
$2.4999
1-Week Range:
$2.35
$2.68
52-Week Range:
$2.35
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.35 | 80.47M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.18 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences Inc 3Q 2026: Net loss $(2.52M), EPS $(0.07) — 10-Q Summary - TradingView
[10-Q] Anixa Biosciences Inc Quarterly Earnings Report - Stock Titan
Number of shareholders of Anixa Biosciences, Inc. – GETTEX:CY71 - TradingView
Anixa Biosciences Holds Steady Near Support as Trading Volume Remains SubduedSuperTrend - The Legal Advocate
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vacci - GuruFocus
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vaccine Technology - GuruFocus
Anixa receives Canadian patent allowance for ovarian cancer vaccine By Investing.com - Investing.com Canada
Anixa receives Canadian patent allowance for ovarian cancer vaccine - Investing.com
Ovarian cancer vaccine targeting 'retired' protein wins Canada patent backing - Stock Titan
Anixa Biosciences (ANIX) Edges Higher, Tests Key Support ZoneArms Index - newsline.com
Anixa Biosciences (ANIX) Holds Steady at $2.73 as Consolidation ContinuesMomentum ETF - The Legal Advocate
Anixa Biosciences (ANIX) Slides 2.15% as Biotech Sector Headwinds ReturnPrice Action Signals - The Legal Advocate
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences Issues Correction to May 11, 2026 Announcement, Details Available on StockTitan.net - geneonline.com
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer Car-T Therapy - marketscreener.com
Anixa Biosciences (ANIX) Reports Promising Survival Data from Cl - GuruFocus
Anixa reports survival data from ovarian cancer therapy trial - Investing.com UK
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - PR Newswire
Anixa reports survival data from ovarian cancer therapy trial By Investing.com - Investing.com Australia
Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial Of Lira-Cel Ovarian Cancer CAR-T Therapy - TradingView
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - StreetInsider
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - Quantisnow
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - The Malaysian Reserve
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Investing News Network
Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ChartMill
Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology - marketscreener.com
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - The AI Journal
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Anixa Biosciences receives Mexican patent for breast cancer vaccine - Investing.com
A breast cancer vaccine gained patent protection in Mexico until 2040 - Stock Titan
Anixa’s ovarian cancer therapy to be presented at ISCT meeting By Investing.com - Investing.com India
Anixa’s ovarian cancer therapy to be presented at ISCT meeting - Investing.com
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - Nasdaq
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - WFXG
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Yahoo Finance
Weekly Trades: Does Anixa Biosciences Inc have declining or rising EPS2026 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Can Anixa Biosciences Inc maintain its current growth rate2026 Analyst Calls & Consistent Profit Trade Alerts - baoquankhu1.vn
AVAX Technologies and Anixa Biosciences Compared in Critical Analysis - National Today
Earnings Risk: Does Anixa Biosciences Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Anixa Biosciences to Participate in RedChip's Biotech Resurgence - GuruFocus
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Finviz
At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):